We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-7.67%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$103M
AUM Growth
-$42.2M
Cap. Flow
-$26.5M
Cap. Flow %
-25.72%
Top 10 Hldgs %
76.67%
Holding
32
New
7
Increased
5
Reduced
13
Closed
6

Top Buys

1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$6.28M
2
AMRN
Amarin Corp
AMRN
+$5.39M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$4.78M
4
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$3.36M
5
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$2.33M

Top Sells

1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$18.9M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$13.8M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$4.15M
4
APEN
Apollo Endosurgery, Inc.
APEN
+$3.54M
5
ALIM
Alimera Sciences
ALIM
+$2.24M

Sector Composition

1 Healthcare 96.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$292M
$18.8M 18.24%
61,978
+15,448
+33% +$5.39M
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$11.3M 11.01%
681,812
+453,912
+199% +$6.28M
BDSI
3
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$10.9M 10.61%
2,595,855
-168,620
-6% -$720K
ENTA icon
4
Enanta Pharmaceuticals
ENTA
$400M
$7.8M 7.57%
129,867
+64,383
+98% +$4.78M
NEOS
5
DELISTED
Neos Therapeutics, Inc
NEOS
$6.66M 6.47%
4,502,301
-468,713
-9% -$759K
CPIX icon
6
Cumberland Pharmaceuticals
CPIX
$102M
$5.1M 4.95%
860,449
-11,313
-1% -$62.9K
APEN
7
DELISTED
Apollo Endosurgery, Inc.
APEN
$4.81M 4.67%
1,463,188
-1,117,330
-43% -$3.54M
OPNT
8
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$4.73M 4.59%
314,073
-1,395
-0.4% -$19.4K
XOMA
9
DELISTED
Xoma
XOMA
$4.54M 4.4%
230,201
-40,248
-15% -$722K
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.29M 4.16%
3,825,903
-287,619
-7% -$335K
HTGM
11
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$3.85M 3.73%
32,168
+16,693
+108% +$3.36M
ADMS
12
DELISTED
Adamas Pharmaceuticals
ADMS
$3.84M 3.73%
751,012
-672,566
-47% -$4.15M
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.11M 3.02%
3,711,999
-192,401
-5% -$147K
LGND icon
14
Ligand Pharmaceuticals
LGND
$6.08B
$2.98M 2.9%
48,034
-220,448
-82% -$13.8M
NVLN
15
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.69M 2.61%
3,703,420
+3,212,324
+654% +$2.33M
APVO icon
16
Aptevo Therapeutics
APVO
$5.91M
– –
0
– –
ALIM
17
DELISTED
Alimera Sciences
ALIM
$1.55M 1.51%
182,694
-246,606
-57% -$2.24M
CORV
18
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.02M 0.99%
+509,356
New +$1.03M
IDXG
19
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$922K 0.89%
116,038
-59,280
-34% -$463K
CHMA
20
DELISTED
Chiasma, Inc. Common Stock
CHMA
$543K 0.53%
+109,743
New +$622K
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$383K 0.37%
+33,033
New +$534K
ACER
22
DELISTED
Acer Therapeutics Inc
ACER
$364K 0.35%
+114,175
New +$335K
TVTX icon
23
Travere Therapeutics
TVTX
$5.27B
$344K 0.33%
+29,675
New +$490K
AFMD
24
DELISTED
Affimed
AFMD
$231K 0.22%
7,850
-63,725
-89% -$1.9M
DRRX
25
DELISTED
DURECT Corp
DRRX
$184K 0.18%
+10,000
New +$135K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Stonepine Capital Management held 32 positions worth $103M, down 29% from $145M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $26.5M in Q3 2019, closing 6 positions and reducing 13 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Correvio Pharma Corp. Ordinary Shares (Canada) worth $1.02M.

  • Stonepine Capital Management's largest Q3 2019 buy was Correvio Pharma Corp. Ordinary Shares (Canada): 509,356 shares worth $1.02M.
  • Stonepine Capital Management added most to Oxford Immunotec Global PLC Ordinary Shares in Q3 2019, an estimated $6.28M increase.
  • Stonepine Capital Management's biggest Q3 2019 reduction was Ligand Pharmaceuticals, cutting an estimated $13.8M.
  • Stonepine Capital Management fully exited Vanda Pharmaceuticals in Q3 2019, selling an estimated $18.9M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $103M portfolio in Q3 2019.
  • Stonepine Capital Management opened 7 new positions and closed 6 in Q3 2019.
  • Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $103M.

Based on Stonepine Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.